Sumitomo Mitsui Trust Group’s Arcturus Therapeutics ARCT Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.2M	Sell	1,963,123 -325,812	-14%	-$2.57M	0.01%	650
2026 Q1	$17.7M	Buy	2,288,935 +262,347	+13%	+$1.91M	0.01%	630
2025 Q4	$12.4M	Buy	2,026,588 +78,753	+4%	+$851K	0.01%	664
2025 Q3	$35.9M	Buy	1,947,835 +115,368	+6%	+$1.85M	0.02%	559
2025 Q2	$23.8M	Sell	1,832,467 -93,617	-5%	-$1.11M	0.01%	617
2025 Q1	$20.4M	Sell	1,926,084 -138,966	-7%	-$2.21M	0.01%	637
2024 Q4	$35M	Sell	2,065,050 -210,665	-9%	-$3.97M	0.02%	541
2024 Q3	$52.8M	Buy	2,275,715 +712,650	+46%	+$15.2M	0.04%	436
2024 Q2	$38.1M	Buy	1,563,065 +286,546	+22%	+$8.69M	0.03%	498
2024 Q1	$43.1M	Sell	1,276,519 -44,133	-3%	-$1.56M	0.03%	534
2023 Q4	$41.6M	Sell	1,320,652 -67,922	-5%	-$1.61M	0.03%	528
2023 Q3	$35.5M	Sell	1,388,574 -16,358	-1%	-$504K	0.03%	551
2023 Q2	$40.3M	Sell	1,404,932 -16,393	-1%	-$446K	0.03%	533
2023 Q1	$34.1M	Sell	1,421,325 -27,735	-2%	-$498K	0.03%	597
2022 Q4	$24.6M	Sell	1,449,060 -10,355	-0.7%	-$181K	0.02%	667
2022 Q3	$21.6M	Buy	1,459,415 +23,221	+2%	+$390K	0.02%	688
2022 Q2	$22.6M	Buy	1,436,194 +34,116	+2%	+$669K	0.02%	696
2022 Q1	$37.8M	Buy	1,402,078 +44,606	+3%	+$1.14M	0.03%	612
2021 Q4	$50.2M	Sell	1,357,472 -1,060	-0.1%	-$43.2K	0.03%	534
2021 Q3	$64.9M	Buy	1,358,532 +143,631	+12%	+$6.44M	0.04%	465
2021 Q2	$41.1M	Buy	1,214,901 +899,089	+285%	+$30.4M	0.02%	598
2021 Q1	$13M	Buy	315,812 +181,208	+135%	+$10.8M	0.01%	756
2020 Q4	$5.84M	Buy	134,604 +3,434	+3%	+$233K	﹤0.01%	826
2020 Q3	$5.63M	Sell	131,170 -15,182	-10%	-$754K	﹤0.01%	812
2020 Q2	$6.84M	Sell	146,352 -108,714	-43%	-$3.75M	﹤0.01%	779
2020 Q1	$3.47M	Sell	255,066 -25,482	-9%	-$326K	﹤0.01%	816
2019 Q4	$3.05M	Sell	280,548 -17,982	-6%	-$188K	﹤0.01%	857
2019 Q3	$3.07M	Buy	298,530 +168,556	+130%	+$1.82M	﹤0.01%	833
2019 Q2	$1.23M	Buy	+129,974	New	+$954K	﹤0.01%	880

Other funds holding ARCT

ELI

Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

MOS

MGO One Seven Beachwood, Ohio $6.06B AUM 28.9% 1-Year Est. Return

AWM

Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return

FCH

Freestone Capital Holdings Seattle, Washington $3.86B AUM 26.3% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

AHL

Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return

Sumitomo Mitsui Trust Group's ARCT Position: Q2 2026 in Review

Sumitomo Mitsui Trust Group reduced its Arcturus Therapeutics (ARCT) stake by 14% in Q2 2026, selling an estimated $2.57M and leaving 1,963,123 shares worth $13.2M. The position accounts for 0.01% of the portfolio, ranked #650.

Sumitomo Mitsui Trust Group first reported a position in ARCT in Q2 2019 and has held it in 29 quarters since. The position peaked at $64.9M in Q3 2021. 29 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

Sumitomo Mitsui Trust Group held 1,963,123 shares of Arcturus Therapeutics worth $13.2M as of Q2 2026.
Sumitomo Mitsui Trust Group sold 325,812 Arcturus Therapeutics shares in Q2 2026, an estimated $2.57M.
Arcturus Therapeutics made up 0.01% of Sumitomo Mitsui Trust Group's portfolio in Q2 2026, its #650 holding.
Sumitomo Mitsui Trust Group first reported a position in Arcturus Therapeutics in Q2 2019 and has held it in 29 quarters since.
Sumitomo Mitsui Trust Group's Arcturus Therapeutics position peaked at $64.9M in Q3 2021.
29 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q2 2026, filed 30 Jul 2026.